Kura Oncology (KURA) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report issued on Wednesday. They currently have $22.00 target price on the stock.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

How to Become a New Pot Stock Millionaire

Several other research firms have also issued reports on KURA. BidaskClub upgraded shares of Kura Oncology from a buy rating to a strong-buy rating in a research report on Thursday, February 22nd. Cann restated a buy rating and issued a $30.00 price target on shares of Kura Oncology in a research report on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the stock a buy rating in a research report on Friday, February 16th. Wedbush began coverage on shares of Kura Oncology in a research report on Tuesday, December 26th. They issued a buy rating and a $19.00 price target on the stock. Finally, ValuEngine lowered shares of Kura Oncology from a hold rating to a sell rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $22.50.

KURA stock opened at $18.45 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 9.44. Kura Oncology has a 12-month low of $5.90 and a 12-month high of $24.02.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01). equities analysts forecast that Kura Oncology will post -1.43 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in Kura Oncology during the 3rd quarter worth approximately $802,000. Alps Advisors Inc. purchased a new position in Kura Oncology during the 4th quarter worth approximately $512,000. American International Group Inc. grew its position in Kura Oncology by 42.0% during the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock worth $208,000 after purchasing an additional 4,012 shares in the last quarter. California State Teachers Retirement System grew its position in Kura Oncology by 24.5% during the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Bailard Inc. purchased a new position in Kura Oncology during the 4th quarter worth approximately $517,000. Hedge funds and other institutional investors own 58.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Kura Oncology (KURA) Upgraded to “Buy” at Zacks Investment Research” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3296095/kura-oncology-kura-upgraded-to-buy-at-zacks-investment-research.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Virtus Investment Partners  Scheduled to Post Quarterly Earnings on Thursday
Virtus Investment Partners Scheduled to Post Quarterly Earnings on Thursday
NXP Semiconductors  Scheduled to Post Quarterly Earnings on Wednesday
NXP Semiconductors Scheduled to Post Quarterly Earnings on Wednesday
CEVA  to Release Earnings on Wednesday
CEVA to Release Earnings on Wednesday
Ottawa Savings Bancorp  Scheduled to Post Earnings on Thursday
Ottawa Savings Bancorp Scheduled to Post Earnings on Thursday
FIG Partners Comments on First Connecticut Bancorp’s FY2018 Earnings
FIG Partners Comments on First Connecticut Bancorp’s FY2018 Earnings
Brokers Offer Predictions for Ramaco Resources’ FY2018 Earnings
Brokers Offer Predictions for Ramaco Resources’ FY2018 Earnings


© 2006-2018 Ticker Report. Google+.